A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

2002/02/01 by Jeffrey R. Currier, Jeffrey R Currier, Ellen G Kuta +12 · 27 citations
Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · #HIV Research and Treatment #Immunotherapy and Immune Responses #vaccines and immunoinformatics approaches

paper · doi:10.1016/s0022-1759(01)00535-x

Cited by

• Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials
• Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE
• Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. [europepmc]
• Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. [europepmc]
• Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. [europepmc]
• Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. [europepmc]
• Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). [europepmc]
• The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. [europepmc]
• Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells. [europepmc]
• Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. [europepmc]
• Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. [europepmc]
• Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. [europepmc]
• Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. [europepmc]
• A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). [europepmc]
• Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. [europepmc]
• Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. [europepmc]
• Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. [europepmc]
• Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. [europepmc]
• A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. [europepmc]
• The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. [europepmc]
• Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. [europepmc]
• TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway. [europepmc]
• Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. [europepmc]
• A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. [europepmc]
• Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. [europepmc]
• Unbiased Screens Show CD8 + T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. [europepmc]
• Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. [europepmc]